Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $12.72, but opened at $12.23. Ginkgo Bioworks shares last traded at $11.85, with a volume of 209,900 shares traded.
Ginkgo Bioworks Stock Up 3.2%
The firm has a fifty day simple moving average of $8.56 and a 200-day simple moving average of $9.13. The company has a market capitalization of $668.94 million, a P/E ratio of -1.24 and a beta of 1.48.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The business had revenue of $48.32 million during the quarter, compared to the consensus estimate of $38.70 million. Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. On average, sell-side analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. SBI Securities Co. Ltd. bought a new position in Ginkgo Bioworks in the fourth quarter valued at approximately $29,000. US Bancorp DE raised its holdings in Ginkgo Bioworks by 43.5% in the 1st quarter. US Bancorp DE now owns 6,302 shares of the company's stock valued at $36,000 after acquiring an additional 1,911 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Ginkgo Bioworks in the 4th quarter valued at $46,000. CWM LLC raised its holdings in shares of Ginkgo Bioworks by 667.6% during the 1st quarter. CWM LLC now owns 12,274 shares of the company's stock worth $70,000 after buying an additional 10,675 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in shares of Ginkgo Bioworks during the 1st quarter worth $76,000. 78.63% of the stock is currently owned by institutional investors.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
